Modulators of the GABAA receptor: Novel therapeutic prospects

Glutamate and GABA Receptors and Transporters: Structure, Function and Pharmacology

Volumn , Issue , 2001, Pages 407-427

  Thomsen, Christian ^a   Ebert, Bjarke ^b  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000846291     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (122)

1. A ion channel function in stably expressed recombinant receptors: constitutive channel opening in the absence of agonist’, Br. J. Pharmacol. 123: 199P.
2. A receptor needs two homologous domains of the [3-subunit for activation by GABA but not by pentobarbital’, Nature 366: 565-569.
3. A receptors’, Presentation at GABA2000 meeting 23 to 29 July. Organisers Peter Gage and Istvan Mody.
4. Benes, F.M. (2000) ‘Emerging principles of altered neural circuitry in schizophrenia’, Brain. Res. Brain. Res. Rev. 31: 251-269.
5. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Loiseau, P. and Perucca, E. (1999) ‘Progress report on new antiepileptic drugs: a summary of the fourth Eilat Conference (EILAT IV)', Epilepsy Res. 34: 1-41.
6. Borden, L.A., Dhar, T.G., Smith, K.E., Branchek, T.A., Gluchowski, C. and Weinshank, R.L. (1994a) ‘Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site’, Receptors and Channels 2: 207-213.
7. Borden, L.A., Murali Dhar, T.G., Smith, K.E., Weinshank, R.L., Branchek, T.A. and Gluchowski, C. (1994b) ‘Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1', Eur. J. Pharmacol. Mol. Pharmacol. 269: 219-224.
8. Borden, L.A., Smith, K. E, Hartig, P.R., Branchek, T.A. and Weinshank, R.L. (1992) ‘Molecular heterogeneity of the -γ-aminobutyric acid (GABA) transport system. Cloning of two novel high affinity GABA transporters from rat brain’, J. Biol. Chem. 267: 21,098-21,104.
9. Borden, L.A., Smith, K.E., Gustafson, E.L., Branchek, T.A. and Weinshank, R.L. (1995a) ‘Cloning and expression of a betaine/GABA transporter from human brain’, J. Neurochem. 64: 977-984.
10. Borden, L.A., Smith, K.E., Vaysse, P.J., Gustafson, E.L., Weinshank, R.L. and Branchek, T.A. (1995b) ‘Re-evaluation of GABA transport in neuronal and glial cell cultures: correlation of pharmacology and mRNA localization’, Receptors and Channels 3: 129-146.
11. Bowery, N.G. and Enna, S.J. (2000) ‘Gamma-aminobutyric acid (B) receptors: first of the functional metabotropic heterodimers’, J. Pharmacol. Exp. Ther. 292: 2-7.
12. Bradford, H.F. (1995) ‘Glutamate, GABA and epilepsy’, Prog. Neurobiol. 47: 477-511.
13. Braestrup, C., Nielsen, E.B., Sonnewald, U., Knutsen, L.J., Andersen, K.E., Jansen, J.A., Frederiksen, K., Andersen, P.H., Mortensen, A. and Suzdak, P.D. (1990) '(R)-N-[4,4-bis (3-methyl-2- thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier’, J. Neurochem. 54: 639-647.
14. Choi, D.W., Farb, D.H. and Fischbach, G.D. (1977) ‘Clordiazepoxide selectively potentiates GABA conductance in spinal cord cell cultures’, Nature 269: 342-344.
15. Choi, D.W., Farb, D.H. and Fischbach, G.D. (1981) ‘Clordiazepoxide selectively potentiates GABA conductance in spinal cord and sensory neurons in cell cultures’, J. Neurophysiol. 45: 621-631.
16. 5 selective inverse agonist’, Presentation at GABA2000 meeting 23 to 29 July. Organisers Peter Gage and Istvan Mody.
17. Costa, E. and Guidotto, A. (1996) ‘Benzodiazepines on trial: a research strategy for their rehabilitation’, Trends Pharmacol. Sci. 17: 192-200.
18. Dalby, N.O. (2000) ‘GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors’, Neuropharmacol. 39: 2399-2407.
19. Dalby, N.O. and Nielsen, E.B. (1997a) ‘Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin’, Epilepsy Res. 28: 63-72.
20. Dalby, N.O. and Nielsen, E.B. (1997b) ‘Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat’, Neurosci. Lett. 229: 135-137.
21. Dalby, N.O., Thomsen, C., Fink-Jensen, A., Lundbeck, J., Søkilde, B., Man, C.M., Sorensen, P.O. and Meldrum, B. (1997) ‘Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1', Epilepsy Res. 28: 51-61.
22. Dalvi, A. and Rodgers, R.J. (1996) ‘GABAergic influences on plus-maze behaviour in mice’, Psychopharmacology 128: 380-397.
23. Dhar, T.G., Borden, L.A., Tyagarajan, S., Smith, K.E., Branchek, T.A., Weinshank, R.L. and Gluchowski, C. (1994) ‘Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3', J. Med. Chem. 37: 2334-2342.
24. Dimmock, P.W., Wyatt, K.W., Jones, P.W. and O’Brien, S (2000) ‘Efficacy of selective serotoninreuptake inhibitors in premenstrual syndrome: a systematic review’, Lancet 356: 1131-1136.
25. Dodrill, C.B., Arnett, J.L., Shu, V., Pixton, G.C., Lenz, G.T. and Sommerville, K.W. (1998) ‘Effects of tiagabine monotherapy on abilities, adjustment, and mood’, Epilepsia 39: 33-42.
26. Dreifuss, F.E. and Ogunyemi, A.O. (1992) ‘Classification of epileptic seizures and the epilepsies: an overview’, Epilepsy Res. Suppl. 6: 3-11.
27. Duncan, G.E., Sheitman, B.B. and Lieberman, J.A. (1999) ‘An integrated view of pathophysiological models of schizophrenia’, Brain Res. Rev. 29: 250-264.
28. Ebert, B., Thompson, S.A., Saounatsou, K., McKernan, R., Krogsgaard-Larsen, P. and Wafford, K.A. (1997) ‘Differences in agonist/antagonist binding affinity and receptor transduction using recombinant human -γ-aminobutyric acid type A receptors’, Mol. Pharmacol. 52: 1150-1156.
29. Ebert, B., Wafford, K.A., Whiting, P.J., Krogsgaard-Larsen, P. and Kemp, J.A. (1994) ‘Molecular pharmacology of -γy-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta and gamma receptor subunit combinations’, Mol. Pharmacol. 46: 957-963.
30. A receptor subtypes in human temporal lobe epilepsy’, J. Neurosci. 20: 5401-5419.
31. Falch, E., Perregaard, J., Frølund, B., Søkilde, B., Buur, A., Hansen, L.M., Frydenvang, K., Brehm L., Bolvig, T., Larsson, O.M., Sanchez, C., White, H.S., Schousboe, A. and Krogsgaard-Larsen, P. (1999) ‘Selective inhibitors of glial GABA uptake: synthesis, absolute stereochemistry, and pharmacology of the enantiomers of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole (exo-THPO) and analogues’, J. Med. Chem. 42: 5402-5414.
32. A agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans’, Psychopharmacol. 130: 285-291.
33. Fink-Jensen, A., Suzdak, P.D., Swedberg, M.D., Judge, M.E., Hansen, L. and Nielsen, P.G. (1992) ‘The -y-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats’, Eur. J. Pharmacol. 220: 197-201.
34. A-receptor subtypes demonstrated in mouse hippocampal and olfactory neurons in vivo’, Neurosci. Lett. 249: 99-102.
35. Gale, K. (1992) ‘Subcortical structures and pathways involved in convulsive seizure generation’, J. Clin. Neurophysiol. 9: 264-277.
36. Gallo, M.A. and Smith, S.S. (1993) ‘Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety’, Pharmacol. Biochem. Behav. 46: 897-904.
37. Green, A.R., Hainsworth, A.H. and Jackson, D.M. (2000) ‘GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke’, Neuropharmacol. 39: 1483-1494.
38. Grunze, H., Erfurth, A., Marcuse, A., Amann, B., Normann, C. and Walden J. (1999) ‘Tiagabine appears not to be efficacious in the treatment of acute mania’, J. Clin. Psychiatry 60: 759-762.
39. Guastella, J., Nelson, N., Nelson, H., Czyzyk, L., Keynan, S., Miedel, M.C., Davidson, N., Lester H.A. and Kanner, B.I. (1990) ‘Cloning and expression of a rat brain GABA transporter’, Science 249: 1303-1306.
40. 6-containing receptors’, Mol. Pharmacol. 49: 253-259.
41. Haefely, W. (1986) ‘Biological basis of drug-induced tolerance, rebound and dependence. Contribution of recent research on benzodiazepines’, Pharmacopsychiatry 90: 353-361.
42. Haefely, W.E. (1989) ‘Pharmacology of the benzodiazepine receptor’, Eur. Arch. Psychiatry. Neurol. Sci. 238: 294-301.
43. Haefely, W., Kulcsar, A., Möhler, H., Pieri, L., Polc, P. and Schaffner, R. (1975) ‘Possible involvement of GABA in the central actions of benzodiazepines’, Adv. Biochem. Psychopharmacol. 14: 131-151.
44. Haefely, W., Pieri, L. and Schaffner, R. (1981) ‘General pharmacology and neuropharmacology of benzodiazepine derivatives’, in F. Hoffmeister and G. Stiller (eds) Handbook of Experimental Pharmacology 55II, Berlin: Springer, pp. 13-262.
45. Hagberg, H., Lehmann, A., Sandberg, M., Nystrom, B., Jacobson, I. and Hamberger, A. (1985) ‘Ischemia-induced shift of inhibitory and excitatory amino acids from intrato extracellular compartments’, J. Cereb. Blood Flow. Metab. 5: 413-419.
46. A receptor occupancy’, Eur. J. Neurosci. 12: 810-818.
47. Halbreich, U., Petty, F., Yonkers, K., Kramer, G.L., Rush, A.J., Bibi, K.W. (1996) ‘Low plasma-γ-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder’, Am. J. Psych. 153: 718-720.
48. 2 subunit of the-γ-aminobutyrate type A receptor’, Neuropharmacol. 38: 253-265.
49. A receptors are preserved in hippocampus of Alzheimer’s disease patients’, J. Neurosci. 98: 669-675.
50. Ikegaki, N., Saito, N., Hashima, M. and Tanaka, C. (1994) ‘Production of specific antibodies against GABA transporter subtypes (GAT1, GAT2, GAT3) and their application to immunocytochemistry’, Mol. Brain. Res. 26: 47-54.
51. Inglefield, J.R., Perry, J.M. and Schwartz, R.D. (1995) ‘Post ischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus’, Hippocampus 5: 460-468.
52. B receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis’, Eur. J. Pharmacol. 368: 205-211.
53. Johansen, F.F., and Diemer, N.H. (1991) ‘Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells’, Acta Neurol. Scand. 84: 1-6.
54. Kalviainen, R. (1998) ‘Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy’, J. Intellect. Disabil. Res. 42: 63-67.
55. Krogsgaard-Larsen, P., Falch, E., Larsson, O.M. and Schousboe, A. (1987) ‘GABA uptake inhibitors: relevance to antiepileptic drug research’, Epilepsy Res. 1: 77-93.
56. A agonist THIP (Gaboxadol) increases non-REM sleep and enhances delta activity in the rat’, Neurorep. 7: 2241-2245.
57. A) agonist 4,5,6, 7-tetra-hydroisoxazolo[4,5-c]pyridin-3-ol persistently increases sleep maintenance and intensity during chronic administration to rats’, J. Pharmacol. Exp. Ther. 293: 1084-1090.
58. A receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats’, Neuropsychopharmacol. 15: 63-74.
59. Lancel, M., Faulhaber, J., Deisz, R.A. (1998) ‘Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat’, Br. J. Pharmacol. 123: 1471-1477.
60. Lancel, M., Faulhaber, J., Schiffelholz, T., Romeo, E., Di Michele, F., Holsboer, F. and Rupprecht R. (1997) ‘Allopregnanolone affects sleep in a benzodiazepine-like fashion’, J. Pharmacol. Exp. Ther. 282: 1213-1218.
61. 1 receptors: involvement in sleep regulation and potential of selective agonists in the treatment of insomnia’, CNS Drugs 13: 185-199.
62. Lin, Z. and Kadaba, P.K. (1997) ‘Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents’, Med. Res. Rev. 17: 537-572.
63. Liu, Q.-R., Lopez-Corcuera, B., Mandiyan, S., Nelson, H. and Nelson, N. (1993) ‘Molecular characterization of four pharmacologically distinct -γ-aminobutyric acid transporters in mouse brain’, J. Biol. Chem. 268: 2106-2112.
64. Loiseau, P. (1999) ‘Review of controlled trials of gabitril (tiagabine): a clinician’s viewpoint’, Epilepsia 40: 14-19.
65. Lopez-Corcuera, B., Liu, Q.-R., Mandiyan, S., Nelson, H. and Nelson, N. (1992) ‘Expression of a mouse brain cDNA encoding novel -γ-aminobutyric acid transporter’, J. Biol. Chem. 267: 17,491-17,503.
66. Löw, K., Crestani, F., Keist, R., Benke, D., Brunig, I., Benson, J.A., Fritschy, J.M., Rulicke, T., Bluethmann, H., Möhler, H. and Rudolph, U. (2000) ‘Molecular and neuronal substrate for the selective attenuation of anxiety’, Science 290: 131-134.
67. B receptor agonists and antagonists’, Clin. Neuropharmacol. 18: 285-305.
68. 1 subtype’, Nat. Neurosci. 3: 587-592.
69. A-receptor subtypes really occur in the brain?', Trends Neurosci. 19: 139-143.
70. Meldrum, B. (1992) ‘Excitatory amino acids in epilepsy and potential novel therapeutics’, Epilepsy Res. 12: 189-196.
71. 6 subunit’, Neuropharmacol. 39: 1495-1513.
72. Mierlack, D. and Farb, D.H. (1988) ‘Modulation of neurotransmitter receptor desensitisation: chlordiazepoxide stimulates fading of the GABA response’, J. Neurosci. 8: 814-820.
73. Miles, R., Toth, K., Gulyas, A.I., Hajos, N. and Freund, T.F. (1996) ‘Differences between somatic and dendritic inhibition in the hippocampus’, Neuron 16: 815-823.
74. Mody, I. (2000) ‘Synaptic actication of GABA-Rs’, Presentation at GABA2000 meeting 23 to 29 July. Organisers Peter Gage and Istvan Mody.
75. A receptors. From subunits to diverse functions’, Ion Channels 4: 89-113.
76. Nelson, N. (1998) ‘The family of Na+/Clneurotransmitter transporters’, J. Neurochem. 71: 1785-803.
77. Nielsen, E.B. (1988) ‘Anxiolytic effect of NO-328, a GABA uptake inhibitor’, Psychopharmacol. 96: S42.
78. 1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression’, Neuroscience 93: 441-448.
79. Olsen, R.W., Bureau, M., Houser, C.R., Delgado-Escueta, A.V., Richards, J.G. and Möhler, H. (1992) ‘GABA/benzodiazepine receptors in human focal epilepsy’, Epilepsy Res. 8: 383-391.
80. Petty, F. (1995) ‘GABA and mood disorders: a brief review and hypothesis’, J. Affect. Disord. 34: 275-281.
81. Phillis, J.W. (1995) ‘CI-966, a GABA uptake inhibitor, antagonizes ischemia-induced neuronal degeneration in the gerbil’, Gen. Pharmacol. 26: 1061-1064.
82. Phillis, J.W., Smith-Barbour, M., Perkins, L.M. and O’Regan, M.H. (1994) ‘Characterization of glutamate, aspartate, and GABA release from ischemic rat cerebral cortex’, Brain Res. Bull. 34: 457-466.
83. Polc, P., Bonetti, E.P., Schaffner, R. and Haefely, W. (1982) ‘A three-state model of the benzo-diazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone’, Naunyn Schmied. Arch. Pharmacol. 321: 260-264.
84. Richards, D. A and Bowery, N.G. (1996) ‘Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus’, Neurochem. Res. 21: 135-140.
85. Rossi, D.J., Oshima, T. and Attwell, D. (2000) ‘Glutamate release in severe brain ischemia is mainly by reversed uptake’, Nature 403: 316-321.
86. A receptor subtypes’, Nature 401: 796-800.
87. B receptors to control rhythmic hippocampal activity’, Neuron 25: 673-681.
88. Schachter, S.C. (1999) ‘A review of the antiepileptic drug tiagabine’, Clin. Neuropharmacol. 22: 312-317.
89. Schaffer, L.C. and Schaffer, C.B. (1999) ‘Tiagabine and the treatment of refractory bipolar disorder’, Am. J. Psychiatry 156: 2014-2015.
90. Schmitt, U. and Hiemke, C. (1999) ‘Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze’, Behav. Pharmacol. 10: 131-137.
91. Sedman, A.J., Gilmet, G.P., Sayed, A.J. and Posvar, E.L. (1990) ‘Initial human safety and tolerance study of a GABA uptake inhibitor, CI-966: potential role of GABA as a mediator in the pathogenesis of schizophrenia and mania’, Drug Dev. Res. 21: 243-252.
92. A receptor channels’, EMBO J. 11: 2017-2023.
93. Simpson, M.D., Slater, P., Deakin, J.F., Gottfries, C.G., Karlsson, I., Grenfeldt, B., and Crow, T.J. (1998) ‘Absence of basal ganglia amino acid neuron deficits in schizophrenia in three collections of brains’, Schizophr. Res. 31: 167-175.
94. A receptor subtypes measured using a novel pH-based high-throughput functional efficacy assay’, J. Neurosci. Methods 99: 91-100.
95. 1Cl-ion flux’, Mol. Pharmacol. 59: 1108-1118.
96. A receptor α subunit’, J. Biol. Chem. 269: 20,380-20,387.
97. Smith, S.E., Parvez, N.S., Chapman, A.G. and Meldrum, B.S. (1995) ‘The -γ-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy’, Eur. J. Pharmacol. 273: 259-265.
98. 4 subunit suppression prevents withdrawal properties of an endogenous steroid’, Nature 392: 926-930.
99. A receptors’, Neurochem. Res. 23: 1283-1290.
100. Stephens, D.N., Schneider, H.H., Kehr, W., Jensen, L.H., Petersen, E. and Honore, T. (1987) ‘Modulation of anxiety by beta-carbolines and other benzodiazepine receptor ligands: relationship of pharmacological to biochemical measures of efficacy’, Brain Res. Bull. 19: 309-318.
101. A receptors in rat brain’, Brain Res. 822: 265-270.
102. A receptor in rat thalamus’, Mol. Pharmacol. 56: 110-115.
103. Suzdak, P. (1993) ‘Lipophilic GABA uptake inhibitors: biochemistry, pharmacology and therapeutic potential’, Drugs of the Future 18: 1129-1136.
104. Suzdak, P.D. and Jansen, J.A. (1995) ‘A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor’, Epilepsia 36: 612-626.
105. Swedberg, M.D. (1994) ‘The mouse grid-shock analgesia test: pharmacological characterization of latency to vocalization threshold as an index of antinociception’, J. Pharmacol. Exp. Ther. 269: 1021-1028.
106. Tamminga, C.A., Crayton, J.W. and Chase, T.N. (1978) ‘Muscimol: GABA agonist in therapy in schizophrenia’, Am. J. Psychiatry 135: 746-747.
107. Teuber, L., Watjens, F. and Jensen, L.H. (1999) ‘Ligands for the benzodiazepine binding site: a survey’, Current Pharm. Des. 5: 317-343.
108. Theobald, W., Busch, O., Kunz, H.A., Krupp, P., Stenger, E.G. and Heinemann, H. (1968) ‘Pharmakologische und experimentalpsychologische untersuchungen mit 2 inhaltsstoffen des fliegenpilzes (amanita muscaria)', Arzneim. Forsch. 18: 311-315.
109. A receptors containing the epsilon-subunit’, Toxicol. Lett. 100: 233-238.
110. Thomsen, C., Sørensen, P.O. and Egebjerg J. (1997) '1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2- methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA- transporter’, Br. J. Pharmacol. 120: 983-985.
111. Uhl, G.R. and Hartig, P.R. (1992) ‘Transporter explosion: update on uptake’, Trends Pharmacol. Sci. 13: 421-425.
112. Verdoorn, T.A. (1994) ‘Formation of heteromeric -γ-aminobutyric acid type A receptors containing two different αsubunits’, Mol. Pharmacol. 45: 475-480.
113. A receptors’, Presentation at GABA2000 meeting 23 to 29 July. Organisers Peter Gage and Istvan Mody.
114. 4 subunit’, Mol. Pharmacol. 50: 670-678.
115. 5 containing receptors: what do they do and what might they be good for?', Presentation at GABA2000 meeting 23 to 29 July. Organisers Peter Gage and Istvan Mody.
116. Whiting, P.J., Bonnert, T.P., McKernan, R.M., Farrar, S., Le Bourdellès, B., Heavens, R.P., Smith, D.W., Hewson, L., Rigby, M.R., Sirinathsinghji, D.J., Thompson, S.A. and Wafford, K.A. (1999) ‘Molecular and functional diversity of the expanding GABA-A receptor gene family’, Ann. NY Acad. Sci. 868: 645-653.
117. A receptor subunit conferring atypical functional properties’, J. Neurosci. 17: 5027-5037.
118. Woo, T.U., Whitehead, R.E., Melchitzky, D.S. and Lewis, D.A. (1998) ‘A subclass of prefrontal-γ-aminobutyric acid axon terminals are selectively altered in schizophrenia’, Proc. Natl. Acad. Sci. USA 28: 5341-5346.
119. Xu, C.W., Yi, Y., Qiu, L. and Shuaib, A. (2000) ‘Neuroprotective activity of tiagabine in a focal embolic model of cerebral ischemia’, Brain Res. 874: 75-77.
120. −-dependent betaine transporter that is regulated by hypertonicity’, J. Biol. Chem. 267: 649-652.
121. Yang, Y., Li, Q., Wang, C.X., Jeerakathil, T. and Shuaib, A. (2000) ‘Dose-dependent neuroprotection with tiagabine in a focal cerebral ischemia model in rat’, Neuroreport 11: 2307-2311.
122. Zorn, S.H. and Enna, S.J. (1985) ‘GABA uptake inhibitors produce a greater antinociceptive response in the mouse tail-immersion assay than other types of GABAergic drugs’, Life Sci. 37: 1901-1912.